(a) SO2 content in rat tissue homogenate (perivascular adipose tissue, perirenal adipose tissue, epididymal adipose tissue, subcutaneous adipose tissue, brown adipose tissue, heart, lung, liver, spleen, kidney and aorta) by HPLC-FD. (b) RT-PCR analysis of AAT1 and AAT2 mRNA levels in rat tissue (perivascular adipose tissue, perirenal adipose tissue, epididymal adipose tissue, subcutaneous adipose tissue, brown adipose tissue, heart, lung, liver, spleen, kidney and aorta). (c) Western blot analysis of AAT1 and AAT2 protein expression in rat tissue homogenate (perivascular adipose tissue, perirenal adipose tissue, epididymal adipose tissue, subcutaneous adipose tissue, brown adipose tissue, heart, lung, liver, spleen, kidney and aorta). The bands of AAT1 and AAT2 were exposed twice. (d) Measurement of SO2 production from different rat tissues by addition of L-cysteine plus pyridoxal 5′-phosphate to tissue homogenate and incubation for 90 min. (e) Expression of AAT1 in different rat tissues using immunohistochemistry: i, perivascular adipose tissue; ii, perirenal adipose tissue; iii, epididymal adipose tissue; iv, subcutaneous adipose tissue; v, brown adipose tissue; vi, heart; vii, liver; viii, aorta; and ix IgG as a negative control. (f) Expression of AAT2 in different rat tissues using immunohistochemistry: i, perivascular adipose tissue; ii, perirenal adipose tissue; iii, epididymal adipose tissue; iv, subcutaneous adipose tissue; v, brown adipose tissue; vi, heart; vii, liver; viii, aorta; and ix IgG as a negative control. (g) Hematoxylin and eosin (HE) staining of different rat tissues: i, perivascular adipose tissue; ii, perirenal adipose tissue; iii, epididymal adipose tissue; iv, subcutaneous adipose tissue; v, brown adipose tissue; vi, heart; vii, liver; and viii aorta.